28
Participants
Start Date
November 30, 2012
Primary Completion Date
December 31, 2015
Study Completion Date
May 31, 2017
MN-166 (50 mg) First
In this arm of the study participants were first maintained on 50 mg MN-166 BID for approximately 14 days, and were then switched onto placebo maintenance. The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo \& MN-166).
Placebo First
This arm of the study participants were first maintained on placebo for approximately 14 days, and were then switched onto 50mg MN-166 BID maintenance. . The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo \& MN-166).
New York State Psychiatric Institute, New York
Collaborators (1)
National Institute on Drug Abuse (NIDA)
NIH
MediciNova
INDUSTRY
New York State Psychiatric Institute
OTHER